Kyahn Williamson
Senior Vice President of Company Communications & Investor Relations
Good morning, and good night, everybody. My identify is Kyahn Williamson, SVP of Investor Relations and Company Communication at Telix. Thanks for becoming a member of our academic webinar on our neurologic oncology portfolio.
Earlier than we start, I wish to word that immediately’s presentation contains forward-looking statements. These forward-looking statements are primarily based on present assumptions, precise outcomes may differ materially. We do advise you to learn the protected harbor assertion.
In the present day, you will be listening to from Richard Valeix, CEO of Telix Therapeutics for a portfolio overview, and this shall be adopted by Dr. David Cade, Group Chief Medical Officer at Telix for a medical replace on our Therapeutic and Precision Drugs candidates within the neurologic oncology portfolio. This shall be adopted by a dialogue with key opinion leaders within the discipline, Dr. Josef Pichler and Dr. Nelleke Tolboom, who David will introduce extra absolutely throughout the session. Following the dialogue, there shall be a reside Q&A the place each David and Richard shall be out there to take your questions.
With that, I would like handy over.
Richard Valeix
Chief Govt Officer of Telix Therapeutics
Thanks, Ky. I am Richard Valeix, the CEO of Telix Therapeutics. As you’ll be able to see, Telix has one of many deepest pipeline within the radiopharmaceutical trade. However let’s focus immediately
